Table of Contents
ISRN Cardiology
Volume 2011 (2011), Article ID 176834, 7 pages
http://dx.doi.org/10.5402/2011/176834
Review Article

Novel Pharmacological Interventions to Maintain Sinus Rhythm after DC Cardioversion

The Department of Cardiology, University Hospital of Wales, Heath Park, Cardiff CF14 4XN Wales, UK

Received 27 March 2011; Accepted 15 May 2011

Academic Editors: O. D. Pedersen and W.-C. Yu

Copyright © 2011 D. E. Thomas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. B. Kannel, R. D. Abbott, D. D. Savage, and P. M. McNamara, “Epidemiologic features of chronic atrial fibrillation: the Framingham study,” The New England Journal of Medicine, vol. 306, no. 17, pp. 1018–1022, 1982. View at Google Scholar · View at Scopus
  2. A. D. Krahn, J. Manfreda, R. B. Tate, F. A. Mathewson, and T. E. Cuddy, “The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba follow-up study,” American Journal of Medicine, vol. 98, no. 5, pp. 476–484, 1995. View at Publisher · View at Google Scholar · View at Scopus
  3. E. J. Benjamin, P. A. Wolf, R. B. D'Agostino, H. Silbershatz, W. B. Kannel, and D. Levy, “Impact of atrial fibrillation on the risk of death: the Framingham heart study,” Circulation, vol. 98, no. 10, pp. 946–952, 1998. View at Google Scholar · View at Scopus
  4. M. C. Wijffels, C. J. Kirchhof, R. Dorland, and M. A. Allessie, “Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats,” Circulation, vol. 92, no. 7, pp. 1954–1968, 1995. View at Google Scholar · View at Scopus
  5. C. A. Morillo, G. J. Klein, D. L. Jones, and C. M. Guiraudon, “Chronic rapid atrial pacing: Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation,” Circulation, vol. 91, no. 5, pp. 1588–1595, 1995. View at Google Scholar · View at Scopus
  6. J. Carlsson, S. Miketic, J. Windeler et al., “Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the strategies of treatment of atrial fibrillation (STAF) study,” Journal of the American College of Cardiology, vol. 41, no. 10, pp. 1690–1696, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. S. H. Hohnloser, K. H. Kuck, and J. Lilienthal, “Rhythm or rate control in atrial fibrillation—pharmacological intervention in atrial fibrillation (PIAF): a randomised trial,” The Lancet, vol. 356, no. 9244, pp. 1789–1794, 2000. View at Google Scholar · View at Scopus
  8. G. Opolski, A. Torbicki, D. A. Kosior et al., “Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish how to treat chronic atrial fibrillation (HOT CAFE) study,” Chest, vol. 126, no. 2, pp. 476–486, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. I. C. van Gelder, V. E. Hagens, H. A. Bosker et al., “A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation,” The New England Journal of Medicine, vol. 347, no. 23, pp. 1834–1840, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. D. G. Wyse, A. L. Waldo, J. P. DiMarco et al., “A comparison of rate control and rhythm control in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 347, no. 23, pp. 1825–1833, 2002. View at Google Scholar · View at Scopus
  11. V. Fuster, L. E. Ryden, D. S. Cannom et al., “ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) Developed in Collaboration with the European Heart Rhythm Association and the Heart Rhythm Society,” Journal of the American College of Cardiology, vol. 48, no. 4, pp. 854–906, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. The National Collaborating Centre for Chronic Conditions, Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care, Royal College of Physicians, London, UK, 2006.
  13. J. Ruskin, P. A. McHale, A. Harley, and J. C. Greenfield Jr., “Pressure-flow studies in man: effect of atrial systole on left ventricular function,” The Journal of Clinical Investigation, vol. 49, no. 3, pp. 472–478, 1970. View at Google Scholar · View at Scopus
  14. W. C. Yu, S. H. Lee, C. T. Tai et al., “Reversal of atrial electrical remodeling following cardioversion of long-standing atrial fibrillation in man,” Cardiovascular Research, vol. 42, no. 2, pp. 470–476, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Alt, R. Ammer, C. Schmitt et al., “A comparison of treatment of atrial fibrillation with low-energy intracardiac cardioversion and conventional external cardioversion,” European Heart Journal, vol. 18, no. 11, pp. 1796–1804, 1997. View at Google Scholar · View at Scopus
  16. B. Wozakowska-Kaplon, M. Janion, J. Sielski, E. Radomska, D. Bakowski, and R. Bartkowiak, “Efficacy of biphasic shock for transthoracic cardioversion of persistent atrial fibrillation: can we predict energy requirements?” Pacing and Clinical Electrophysiology, vol. 27, no. 6 part 1, pp. 764–768, 2004. View at Google Scholar · View at Scopus
  17. G. R. Dagenais, S. Yusuf, M. G. Bourassa et al., “Effects of ramipril on coronary events in high-risk persons: results of the heart outcomes prevention evaluation study,” Circulation, vol. 104, no. 5, pp. 522–526, 2001. View at Google Scholar · View at Scopus
  18. M. Packer, P. A. Poole-Wilson, P. W. Armstrong et al., “Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group,” Circulation, vol. 100, no. 23, pp. 2312–2318, 1999. View at Google Scholar
  19. K. Wachtell, B. Hornestam, M. Lehto et al., “Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan intervention for end point reduction in hypertension (LIFE) study,” Journal of the American College of Cardiology, vol. 45, no. 5, pp. 705–711, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. K. Wachtell, M. Lehto, E. Gerdts et al., “Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan intervention for end point reduction in hypertension (LIFE) study,” Journal of the American College of Cardiology, vol. 45, no. 5, pp. 712–719, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. K. M. Fox, “Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study),” The Lancet, vol. 362, no. 9386, pp. 782–788, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Jong, S. Yusuf, M. F. Rousseau, S. A. Ahn, and S. I. Bangdiwala, “Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study,” The Lancet, vol. 361, no. 9372, pp. 1843–1848, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. M. A. Pfeffer, K. Swedberg, C. B. Granger et al., “Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme,” The Lancet, vol. 362, no. 9386, pp. 759–766, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Gurlek, C. Erol, and E. Basesme, “Antiarrhythmic effect of converting enzyme inhibitors in congestive heart failure,” International Journal of Cardiology, vol. 43, no. 3, pp. 315–318, 1994. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Vermes, J. C. Tardif, M. G. Bourassa et al., “Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials,” Circulation, vol. 107, no. 23, pp. 2926–2931, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. O. D. Pedersen, H. Bagger, L. Kober, and C. Torp-Pedersen, “Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction,” Circulation, vol. 100, no. 4, pp. 376–380, 1999. View at Google Scholar · View at Scopus
  27. A. H. Madrid, J. Peng, J. Zamora et al., “The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials,” Pacing and Clinical Electrophysiology, vol. 27, no. 10, pp. 1405–1410, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. A. H. Madrid, M. G. Bueno, J. M. Rebollo et al., “Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study,” Circulation, vol. 106, no. 3, pp. 331–336, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. K. C. Ueng, T. P. Tsai, W. C. Yu et al., “Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: results of a prospective and controlled study,” European Heart Journal, vol. 24, no. 23, pp. 2090–2098, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Deroubaix, T. Folliguet, C. Rucker-Martin et al., “Moderate and chronic hemodynamic overload of sheep atria induces reversible cellular electrophysiologic abnormalities and atrial vulnerability,” Journal of the American College of Cardiology, vol. 44, no. 9, pp. 1918–1926, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. M. Hirose, Y. Takeishi, T. Miyamoto, I. Kubota, K. R. Laurita, and S. Chiba, “Mechanism for atrial tachyarrhythmia in chronic volume overload-induced dilated atria,” Journal of Cardiovascular Electrophysiology, vol. 16, no. 7, pp. 760–769, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. D. Li, S. Fareh, T. K. Leung, and S. Nattel, “Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort,” Circulation, vol. 100, no. 1, pp. 87–95, 1999. View at Google Scholar · View at Scopus
  33. F. Ravelli and M. Allessie, “Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart,” Circulation, vol. 96, no. 5, pp. 1686–1695, 1997. View at Google Scholar · View at Scopus
  34. S. Verheule, E. Wilson, T. Everett, S. Shanbhag, C. Golden, and J. Olgin, “Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation,” Circulation, vol. 107, no. 20, pp. 2615–2622, 2003. View at Google Scholar · View at Scopus
  35. M. W. Webster, M. A. Fitzpatrick, M. G. Nicholls, H Ikram, and J. E. Wells, “Effect of enalapril on ventricular arrhythmias in congestive heart failure,” American Journal of Cardiology, vol. 56, no. 8, pp. 566–569, 1985. View at Google Scholar
  36. D. E. Dostal, “Regulation of cardiac collagen: angiotensin and cross-talk with local growth factors,” Hypertension, vol. 37, no. 3, pp. 841–844, 2001. View at Google Scholar · View at Scopus
  37. N. Hanna, S. Cardin, T. K. Leung, and S. Nattel, “Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure,” Cardiovascular Research, vol. 63, no. 2, pp. 236–244, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. S. Verheule, T. Sat, T. Everett et al., “Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-β1,” Circulation Research, vol. 94, no. 11, pp. 1458–1465, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. A. Frustaci, C. Chimenti, F. Bellocci, E. Morgante, M. A. Russo, and A. Maseri, “Histological substrate of atrial biopsies in patients with lone atrial fibrillation,” Circulation, vol. 96, no. 4, pp. 1180–1184, 1997. View at Google Scholar · View at Scopus
  40. W. W. Brooks, O. H. Bing, K. G. Robinson, M. T. Slawsky, D. M. Chaletsky, and C. H. Conrad, “Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat,” Circulation, vol. 96, no. 11, pp. 4002–4010, 1997. View at Google Scholar · View at Scopus
  41. D. Grimm, S. R. Holmer, G. A. Riegger, and E. P. Kromer, “Effects of beta-receptor blockade and angiotensin II type I receptor antagonism in isoproterenol—induced heart failure in the rat,” Cardiovascular Pathology, vol. 8, no. 6, pp. 315–323, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. C. van Krimpen, J. F. Smits, J. P. Cleutjens et al., “DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: effects of captopril,” Journal of Molecular and Cellular Cardiology, vol. 23, no. 11, pp. 1245–1253, 1991. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Mizuno, M. Yoshimura, H. Yasue et al., “Aldosterone production is activated in failing ventricle in humans,” Circulation, vol. 103, no. 1, pp. 72–77, 2001. View at Google Scholar · View at Scopus
  44. P. Milliez, X. Girerd, P. F. Plouin, J. Blacher, M. E. Safar, and J. J. Mourad, “Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism,” Journal of the American College of Cardiology, vol. 45, no. 8, pp. 1243–1248, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. P. Milliez, N. DeAngelis, C. Rucker-Martin et al., “Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction,” European Heart Journal, vol. 26, no. 20, pp. 2193–2199, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. S. C. Shroff, K. Ryu, N. L. Martovitz, B. D. Hoit, and B. S. Stambler, “Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure,” Journal of Cardiovascular Electrophysiology, vol. 17, no. 5, pp. 534–541, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. M. A. Allessie, “Atrial electrophysiologic remodeling: another vicious circle?” Journal of Cardiovascular Electrophysiology, vol. 9, no. 12, pp. 1378–1393, 1998. View at Google Scholar · View at Scopus
  48. M. Haissaguerre, P. Jais, D. C. Shah et al., “Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins,” The New England Journal of Medicine, vol. 339, no. 10, pp. 659–666, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. W. J. Lammers, M. J. Schalij, C. J. Kirchhof, and M. A. Allessie, “Quantification of spatial inhomogeneity in conduction and initiation of reentrant atrial arrhythmias,” American Journal of Physiology, vol. 259, no. 4, part 2, pp. H1254–H1263, 1990. View at Google Scholar · View at Scopus
  50. M. E. Dibner-Dunlap, M. L. Smith, T. Kinugawa, and M. D. Thames, “Enalaprilat augments arterial and cardiopulmonary baroreflex control of sympathetic nerve activity in patients with heart failure,” Journal of the American College of Cardiology, vol. 27, no. 2, pp. 358–364, 1996. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Lombardi, A. Colombo, B. Basilico et al., “Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversion,” Journal of the American College of Cardiology, vol. 37, no. 1, pp. 157–162, 2001. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Benardeau, S. N. Hatem, C. Rucker-Martin et al., “Contribution of Na+/Ca2+ exchange to action potential of human atrial myocytes,” American Journal of Physiology, vol. 271, no. 3, part 2, pp. H1151–H1161, 1996. View at Google Scholar · View at Scopus
  53. Y. J. Chen, S. A. Chen, Y. C. Chen et al., “Effects of rapid atrial pacing on the arrhythmogenic activity of single cardiomyocytes from pulmonary veins: implication in initiation of atrial fibrillation,” Circulation, vol. 104, no. 23, pp. 2849–2854, 2001. View at Google Scholar · View at Scopus
  54. R. M. Touyz, P. Sventek, R. Lariviere et al., “Cytosolic calcium changes induced by angiotensin II in neonatal rat atrial and ventricular cardiomyocytes are mediated via angiotensin II subtype 1 receptors,” Hypertension, vol. 27, no. 5, pp. 1090–1096, 1996. View at Google Scholar · View at Scopus
  55. A. G. Zaman, M. T. Kearney, C. Schecter, S. G. Worthley, and J. Nolan, “Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation,” American Heart Journal, vol. 147, no. 5, pp. 823–827, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. M. Grecu, R. O. Olteanu, S. S. Olteanu, and C. A. Georgescu, “Does treatment with ACE inhibitors prevent the long term recurrences of lone atrial fibrillation after cardioversion?” Romanian Journal of Internal Medicine, vol. 45, no. 1, pp. 29–33, 2007. View at Google Scholar · View at Scopus
  57. A. Tveit, I. Grundvold, M. Olufsen et al., “Candesartan in the prevention of relapsing atrial fibrillation,” International Journal of Cardiology, vol. 120, no. 1, pp. 85–91, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. M. Disertori, R. Latini, S. Barlera et al., “Valsartan for prevention of recurrent atrial fibrillation,” The New England Journal of Medicine, vol. 360, no. 16, pp. 1606–1617, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. M. P. van den Berg, H. J. Cruns, D. J. van Veldhuisen, N. Griep, P. J. De Kam, and K. I. Lie, “Effects of lisinopril in patients with heart failure and chronic atrial fibrillation,” Journal of Cardiac Failure, vol. 1, no. 5, pp. 355–363, 1995. View at Google Scholar
  60. F. Belluzzi, L. Sernesi, P. Preti, F. Salinaro, M. L. Fonte, and S. Perlini, “Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients,” Journal of the American College of Cardiology, vol. 53, no. 1, pp. 24–29, 2009. View at Publisher · View at Google Scholar · View at PubMed
  61. R. P. Tracy, “Inflammation in cardiovascular disease: cart, horse, or both?” Circulation, vol. 97, no. 20, pp. 2000–2002, 1998. View at Google Scholar
  62. P. M. Ridker, N. Rifai, and S. P. Lowenthal, “Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia,” Circulation, vol. 103, no. 9, pp. 1191–1193, 2001. View at Google Scholar
  63. G. Liuzzo, L. M. Biasucci, J. R. Gallimore et al., “The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina,” The New England Journal of Medicine, vol. 331, no. 7, pp. 417–424, 1994. View at Publisher · View at Google Scholar · View at PubMed
  64. M. Nikfardjam, M. Müllner, W. Schreiber et al., “The association between C-reactive protein on admission and mortality in patients with acute myocardial infarction,” Journal of Internal Medicine, vol. 247, no. 3, pp. 341–345, 2000. View at Publisher · View at Google Scholar
  65. P. Bruins, H. Te Velthuis, A. P. Yazdanbakhsh et al., “Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves c-reactive protein and is associated with postoperative arrhythmia,” Circulation, vol. 96, no. 10, pp. 3542–3548, 1997. View at Google Scholar
  66. J. L. Anderson, C. A. Allen Maycock, D. L. Lappé et al., “Frequency of elevation of C-reactive protein in atrial fibrillation,” American Journal of Cardiology, vol. 94, no. 10, pp. 1255–1259, 2004. View at Publisher · View at Google Scholar · View at PubMed
  67. F. W. Asselbergs, M. P. van den Berg, G. F. H. Diercks, W. H. van Gilst, and D. J. van Veldhuisen, “C-reactive protein and microalbuminuria are associated with atrial fibrillation,” International Journal of Cardiology, vol. 98, no. 1, pp. 73–77, 2005. View at Publisher · View at Google Scholar · View at PubMed
  68. D. S. G. Conway, P. Buggins, E. Hughes, and G. Y. H. Lip, “Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation,” Journal of the American College of Cardiology, vol. 43, no. 11, pp. 2075–2082, 2004. View at Publisher · View at Google Scholar · View at PubMed
  69. J. Dernellis and M. Panaretou, “C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation,” Acta Cardiologica, vol. 56, no. 6, pp. 375–380, 2001. View at Google Scholar
  70. S. N. Psychari, T. S. Apostolou, L. Sinos, E. Hamodraka, G. Liakos, and D. T. Kremastinos, “Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation,” American Journal of Cardiology, vol. 95, no. 6, pp. 764–767, 2005. View at Publisher · View at Google Scholar · View at PubMed
  71. T. Watanabe, Y. Takeishi, O. Hirono et al., “C-Reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation,” Heart and Vessels, vol. 20, no. 2, pp. 45–49, 2005. View at Publisher · View at Google Scholar · View at PubMed
  72. M. K. Chung, D. O. Martin, D. Sprecher et al., “C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation,” Circulation, vol. 104, no. 24, pp. 2886–2891, 2001. View at Google Scholar
  73. Y. Nakamura, K. Nakamura, K. Fukushima-Kusano et al., “Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis,” Thrombosis Research, vol. 111, no. 3, pp. 137–142, 2003. View at Publisher · View at Google Scholar
  74. J. Dernellis and M. Panaretou, “Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation,” European Heart Journal, vol. 25, no. 13, pp. 1100–1107, 2004. View at Publisher · View at Google Scholar · View at PubMed
  75. T. E. Strandberg, H. Vanhanen, and M. J. Tikkanen, “Effect of statins on C-reactive protein in patients with coronary artery disease,” The Lancet, vol. 353, no. 9147, pp. 118–119, 1999. View at Publisher · View at Google Scholar
  76. J. K. Plenge, T. L. Hernandez, K. M. Weil et al., “Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction,” Circulation, vol. 106, no. 12, pp. 1447–1452, 2002. View at Publisher · View at Google Scholar
  77. C. W. Siu, C. P. Lau, and H. F. Tse, “Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion,” American Journal of Cardiology, vol. 92, no. 11, pp. 1343–1345, 2003. View at Publisher · View at Google Scholar
  78. H. Sinno, K. Derakhchan, D. Libersan, Y. Merhi, T. K. Leung, and S. Nattel, “Atrial ischemia promotes atrial fibrillation in dogs,” Circulation, vol. 107, no. 14, pp. 1930–1936, 2003. View at Publisher · View at Google Scholar · View at PubMed
  79. J. M. J. Lamers, J. M. Hartog, P. D. Verdouw, and W. C. Hulsmann, “Dietary fatty acids and myocardial function,” Basic Research in Cardiology, vol. 82, no. 1, pp. 209–221, 1987. View at Google Scholar
  80. E. M. Pound, J. X. Kang, and A. Leaf, “Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes,” Journal of Lipid Research, vol. 42, no. 3, pp. 346–351, 2001. View at Google Scholar
  81. D. Mozaffarian, B. M. Psaty, E. B. Rimm et al., “Fish intake and risk of incident atrial fibrillation,” Circulation, vol. 110, no. 4, pp. 368–373, 2004. View at Publisher · View at Google Scholar · View at PubMed
  82. R. A. Harrison and P. J. Elton, “Is there a role for long-chain ω3 or oil-rich fish in the treatment of atrial fibrillation?” Medical Hypotheses, vol. 64, no. 1, pp. 59–63, 2005. View at Publisher · View at Google Scholar · View at PubMed
  83. A. Jahangiri, W. R. Leifert, G. S. Patten, and E. J. McMurchie, “Termination of asynchronous contractile activity in rat atrial myocytes by n-3 polyunsaturated fatty acids,” Molecular and Cellular Biochemistry, vol. 206, no. 1-2, pp. 33–41, 2000. View at Google Scholar
  84. C. M. Albert, H. Campos, M. J. Stampfer et al., “Blood levels of long-chain n-3 fatty acids and the risk of sudden death,” The New England Journal of Medicine, vol. 346, no. 15, pp. 1113–1118, 2002. View at Publisher · View at Google Scholar · View at PubMed
  85. R. Marchioli, F. Barzi, E. Bomba et al., “Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo studio della sopravvivenza nell'infarto miocardico (GISSI)-prevenzione,” Circulation, vol. 105, no. 16, pp. 1897–1903, 2002. View at Publisher · View at Google Scholar
  86. L. Calò, L. Bianconi, F. Colivicchi et al., “N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial,” Journal of the American College of Cardiology, vol. 45, no. 10, pp. 1723–1728, 2005. View at Publisher · View at Google Scholar · View at PubMed